pharma · Refractory Partial Onset Epilepsy · Multiple Sclerosis
NEURAXPHARM AUSTRALIA PTY
NEURAXPHARM AUSTRALIA PTY LIMITED
Neurizon Therapeutics is a pharma organization headquartered in Melbourne, AU. Primary therapeutic focus areas include Refractory Partial Onset Epilepsy, Multiple Sclerosis. NovaPharmaNews links 3 clinical program(s), 1
Melbourne, AU HQ
11 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Melbourne, AU
- Employees
- 11
- Programs
- 3
- Drugs
- 17
- Patents
- 0
NXPLEVE/24/P3-6
Phase 3 · small molecule · Refractory Partial Onset Epilepsy
NXPLEVE/24/P3-6 for Refractory Partial Onset Epilepsy is a Phase 3 program (small_molecule) at NEURAXPHARM AUSTRALIA PTY LIMITED with 1 ClinicalTrials.gov record(s).
Internal code NXPLEVE/24/P3-6
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- NEURAXPHARM AUSTRALIA PTY LIMITED
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Refractory Partial Onset Epilepsy
- Status
- active
- Trials
- 1